Metabolic Imaging with 18F-FDG-PET in Patients with Imatinib-Resistant Gastrointestinal Stromal Tumor.

The article presents a synopsis of a research study originally published in the "Journal of Clinical Oncology". The study focuses on the gastrointestinal stromal tumors (GISTs) and its treatment. GISTs are the most common soft tissue sarcomas and its treatment is dependent on the various stages of cancer. In metastatic cancer, imatinib mesylate is the most effective treatment as it reduces the tumors however the patients show the tumor progression within two years of the treatment. But for the second line treatment, sunitinib malate was used to treat imatinib-resistant metastatic GISTs.